From Seeking Alpha
April 14, 2020
Preliminary results for the 10 µg and 30 µg dose levels showed seroconversion (antibodies develop and are detectable) rates of 94% and 100%, respectively, while being well-tolerated.
The NIH-led Phase 1 study of its COVID-19 vaccine candidate, mRNA-1273, remains on track with enrollment at the highest dose.
The company says its prophylactic vaccines have demonstrated immunogenicity against all eight viruses targeted thus far.
It has nine candidates in development for RSV (older adults and young children), human metapneumovirus and parainfluenza virus type 3, coronavirus, influenza H7N9, CMV, Zika and Epstein-Barr.